Vancouver, BC / ACCESSWIRE / May 23, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CSE: ATT), the Company announces that it is cancelling its proposed dilutive non-brokered private placement for the issuance of up to 2 million units at a price of one dollar per unit originally announced on April 23rd, 2014. This financing is being cancelled due to current fluctuating market prices and the Company's lack of immediate need for funds.
About Abattis Bioceuticals Corp.
Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions by supplying and partnering with companies to employ its vertical cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The company also has an extensive pipeline of high-quality products and Intellectual Property for the rapidly expanding botanical drug market. We follow strict Standard Operating Protocols and adhere to the Law's of Canada and Foreign Jurisdictions. For more information, visit the Company's website at www.abattis.com.
ON BEHALF OF THE BOARD
President & CEO
For further information, contact the Company's CEO, Michael Withrow at (778) 896-6536 or at [email protected]